Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Semi-Rigid Spine Systems Will Escape PMAs, But Not Clinical Mandate

Executive Summary

US FDA has completed a long-running effort to reclassify pedicle screw systems, which are widely used devices for spine fusion procedures. The final policy: all pedicle screws intended as an adjunct to fusion surgery are class II/special controls devices, but "semi-rigid" systems will require clinical data to support 510(k) clearance while more traditional, rigid systems will not.

You may also be interested in...



Industry Urges FDA To Downclassify PEEK Rods For Spinal Fusion

PEEK, or polyether ether ketone, rods should be set as class II devices along with metallic, rigid pedicle screws, rather than put to class III with dynamic spine stabilization systems, companies say, responding to an FDA proposed order.

PMAs Proposed For Dynamic Spine Stabilization Devices

The agency proposes to maintain 510(k) standards for rigid pedicle screw systems but wants dynamic spine stabilization devices, designed to provide more motion and flexibility, to go the PMA route.

Panel Rejects Zimmer's Dynesys Spine Stabilization Device

FDA should not approve Zimmer's Dynesys spine stabilization system as a stand-alone treatment for degenerative spine-related leg pain due to insufficient safety and efficacy data, according to the agency's Orthopedic and Rehabilitation Devices Panel

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel